[1]陈 晨,陈 曦,吴 强.吸入用布地奈德混悬液联合吸入用异丙托溴铵溶液治疗小儿急性支气管炎的临床疗效及不良反应[J].医学信息,2024,37(15):123-126.[doi:10.3969/j.issn.1006-1959.2024.15.028]
　CHEN Chen,CHEN Xi,WU Qiang.Clinical Efficacy and Adverse Reactions of Budesonide Suspension for Inhalation Combined with Ipratropium Bromide Solution for Inhalation in the Treatment of Acute Bronchitis in Children[J].Journal of Medical Information,2024,37(15):123-126.[doi:10.3969/j.issn.1006-1959.2024.15.028]
点击复制

吸入用布地奈德混悬液联合吸入用异丙托溴铵溶液治疗小儿急性支气管炎的临床疗效及不良反应()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年15期
页码:
123-126
栏目:
论著
出版日期:
2024-08-01

文章信息/Info

Title:
Clinical Efficacy and Adverse Reactions of Budesonide Suspension for Inhalation Combined with Ipratropium Bromide Solution for Inhalation in the Treatment of Acute Bronchitis in Children
文章编号:
1006-1959（2024）15-0123-04
作者:
陈 晨; 陈 曦; 吴 强
（湖口县人民医院药剂科1，儿科2，江西 湖口 332500）
Author(s):
CHEN Chen; CHEN Xi; WU Qiang
(Department of Pharmacy1,Department of Pediatrics2,Hukou County People’s Hospital,Hukou 332500,Jiangxi,China)
关键词:
吸入用布地奈德混悬液; 吸入用异丙托溴铵溶液; 急性支气管炎
Keywords:
Budesonide suspension for inhalation; Ipratropium bromide solution for inhalation; Acute bronchitis
分类号:
R725.6
DOI:
10.3969/j.issn.1006-1959.2024.15.028
文献标志码:
A
摘要:
目的 观察吸入用布地奈德混悬液联合吸入用异丙托溴铵溶液治疗小儿急性支气管炎的临床疗效及不良反应。方法 选取2019年3月-2023年3月我院诊治的60例急性支气管炎小儿为研究对象，采用随机数字表法分为对照组（n=30）和观察组（n=30），对照组采用吸入用异丙托溴铵溶液治疗，观察组在对照组基础上联合应用吸入用布地奈德混悬液，比较两组临床疗效、临床症状（咳嗽、咳痰、气促）消失时间、肺功能指标[用力肺活量（FVC）、1 s用力呼气容积（FEV1）及呼吸峰流速（PEF）]、不良反应发生率。结果 观察组治疗总有效率为93.33%，高于对照组的80.00%（P＜0.05）；观察组咳嗽、咳痰、气促消失时间均短于对照组（P＜0.05）；两组治疗后FVC、FEV1、PEF均高于治疗前，且观察组高于对照组（P＜0.05）；观察组不良反应发生率与对照组比较，差异无统计学意义（P＞0.05）。结论 吸入用布地奈德混悬液联合异丙托溴铵溶液治疗小儿急性支气管炎的效果确切，可改善肺功能，促进临床症状快速消失，且不增加不良反应发生率，具有良好的应用安全性和有效性。
Abstract:
Objective To observe the clinical efficacy and adverse reactions of budesonide suspension for inhalation combined with ipratropium bromide solution for inhalation in the treatment of acute bronchitis in children.Methods Sixty children with acute bronchitis diagnosed and treated in our hospital from March 2019 to March 2023 were selected as the research objects. They were divided into control group (n=30) and observation group (n=30) by random number table method. The control group was treated with ipratropium bromide solution for inhalation, and the observation group was combined with budesonide suspension for inhalation on the basis of the control group. The clinical efficacy, disappearance time of clinical symptoms (cough, sputum, shortness of breath), pulmonary function indexes [forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and peak expiratory flow (PEF)] and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 93.33%, which was higher than 80.00% in the control group (P<0.05). The disappearance time of cough, sputum and shortness of breath in the observation group was shorter than that in the control group (P<0.05). After treatment, FVC, FEV1 and PEF in the two groups were higher than those before treatment, and those in the observation group were higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05).Conclusion Budesonide suspension for inhalation combined with ipratropium bromide solution is effective in the treatment of acute bronchitis in children, which can improve lung function, promote the rapid disappearance of clinical symptoms, and does not increase the incidence of adverse reactions. It has good application safety and effectiveness.

参考文献/References:

[1]Kinkade S,Long NA.Acute Bronchitis[J].Am Fam Physician,2016,94(7):560-565.[2]Llor C,Bjerrum L.Antibiotic prescribing for acute bronchitis[J].Expert Rev Anti Infect Ther,2016,14(7):633-642.[3]Smith SM,Fahey T,Smucny J,et al.Antibiotics for acute bronchitis[J].Cochrane Database Syst Rev,2017,6(6):CD000245.[4]程小宁,薛静,马选鹏.伊可新滴剂联合普米克令舒治疗毛细支气管炎患儿的疗效及其对血清 SIL-2R、CysLTs、Eotaxin的影响[J].实用药物与临床,2019,22(7):722-725.[5]杨倩,徐迎军,邹洋,等.金振口服液联合布地奈德液雾化吸入治疗小儿急性支气管炎的疗效及对肺功能和炎症指标的影响[J].现代生物医学进展,2022,22(10):1956-1959.[6]曹丽丽.布地奈德混悬液联合硫酸沙丁胺醇吸入治疗慢性阻塞性肺疾病80例效果观察[J].中国处方药,2018,16(10):86-87.[7]张均.吸入用布地奈德混悬液联合异丙托溴铵雾化对小儿毛细支气管炎的疗效影响分析[J].中国处方药,2020,18(6):118-119.[8]王雄康.肺力咳合剂联合布地奈德雾化吸入治疗小儿急性支气管炎的临床效果观察[J].实用中西医结合临床,2023,23(18):102-105.[9]王朝阳.M胆碱受体阻断剂联合吸入用布地奈德混悬液对支气管哮喘急性发作患儿症状改善及肺功能的影响[J].哈尔滨医药,2022,42(5):79-80.[10]杜建波,陆艳燕,王艳会.小青龙汤联合雾化吸入布地奈德混悬液治疗小儿急性支气管炎的疗效观察[J].检验医学与临床,2016,13(20):2970-2971.[11]陈平兰.布地奈德混悬液联合异丙托溴铵雾化吸入治疗小儿支气管炎临床疗效与安全性研究[J].医学信息,2023,36(8):147-150.[12]赵蓓,童人杰,张春芬,等.布地奈德、阿奇霉素联合特布他林治疗小儿急性支气管炎的临床观察[J].中国药房,2016,27(18):2519-2520,2521. [13]韩传映,李琳,李艳阁,等.小儿咳喘宁口服液联合特布他林治疗儿童急性支气管炎的临床研究[J].现代药物与临床,2023,38(2):378-382.[14]王雷,陆振,韩梅,等.丙酸倍氯米松与布地奈德联合特布他林、异丙托溴胺雾化吸入治疗小儿急性支气管炎喘息症状的疗效对比研究[J].泰山医学院学报,2019,40(12):961-962.[15]孙亮.布地奈德联合特布他林雾化吸入治疗小儿喘息性支气管炎的疗效[J].中国医药科学,2020,10(1):97-99.[16]伍祥胡,梁霞,凌洁萍.异丙托溴铵溶液、沙丁胺醇、布地奈德混悬液联合雾化吸入治疗小儿毛细支气管炎的效果研究[J].解放军预防医学杂志,2019,37(4):114-115.[17]陈成,邹责雄,林慧祺.吸入用布地奈德混悬液联合复方异丙托溴铵气雾剂治疗小儿哮喘性支气管炎[J].深圳中西医结合杂志,2020,30(20):168-169.[18]陈晓云.布地奈德混悬液联合异丙托溴铵溶液雾化吸入治疗小儿急性喘息性支气管炎的临床价值探讨[J].基层医学论坛,2019,23(35):5095-5096.[19]邓志考,王秋芳,何英,等.布地奈德联合氨溴索雾化吸入治疗小儿急性支气管炎的疗效评价[J].齐齐哈尔医学院学报,2016,37(26):3299-3301.[20]寇静利.阿奇霉素干混悬剂联合吸入用布地奈德混悬液、硫酸特布他林雾化液治疗小儿中重度毛细支气管炎的效果[J].临床医学,2022,42(9):112-114.

更新日期/Last Update: 1900-01-01